StockWatch
·

Shree Ganesh Remedies Ltd

BSE: 540737

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
24.70
+61.5%-20.3%
Expenditure
22.44
+63.0%-7.6%
Net Profit
1.63
+45.9%-67.0%
OPM %
16.90%
-6.44pp-14.83pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.009.5819.1628.7438.32Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

SGR Q2FY27: PAT -67% YoY to ₹1.63 Cr, OPM halves despite Block-7-led revenue rebound

speciality chemicals · api intermediates · margin compression

ResultsQ2 FY2731 Oct 20263 minPharma & Healthcare

Shree Ganesh Remedies Q1FY27: consolidated PAT -67% YoY, revenue -42% ahead of Block-7 ramp

api intermediates · specialty chemicals · margin compression

ResultsQ1 FY2712 Aug 20263 minPharma & Healthcare
Latest
Board Meeting31 Oct, 5:31 pm

Shree Ganesh Remedies Q2 FY27: Consolidated PAT Falls 67% YoY as Margins Nearly Halve

Shree Ganesh Remedies' consolidated Q2 FY27 (quarter ended September 30, 2026) revenue from operations came in at ₹23.29 Cr, down 23.2% YoY from ₹30.32 Cr, while consolidated PAT fell 67.1% YoY to ₹1.63 Cr from ₹4.96 Cr — the YoY decline remains broad-based even though both lines rebounded sharply sequentially (revenue +62.2% QoQ, PAT +45.5% QoQ) off a weak Q1 FY27 base that was itself down 42% YoY. Standalone and consolidated results are closely aligned (PAT ₹1.6346 Cr standalone vs ₹1.6299 Cr consolidated), so there is no basis divergence to flag. The YoY decline is concentrated in margins rather than volumes alone: operating margin (OPM) compressed to roughly 16.9% from 31.7% a year ago and 23.3% last quarter, and net margin (NPM) fell to 7.0% from 16.0% YoY. With cost of materials and other expenses rising faster than revenue even as revenue recovered sequentially, the squeeze sits on the gross/operating line rather than tax or finance costs, whose share of revenue stayed comparatively stable. No exceptional items, minority-interest swings, or other one-offs are disclosed in this filing, so the entire YoY move in PAT reflects this margin compression plus the smaller revenue base. No broker previews or consensus estimates for this specific quarter turned up in search, so vsStreet is unknown — this is a small-cap with limited visible analyst coverage. Against management's own framing from the Q4 FY26 concall — a 'gradual improvement in momentum through FY27' driven by new Block-7 capacity commencing production in Q2 FY27 and CRAMS traction building later in the year, with a long-term EBITDA margin target of 26-28% — the quarter is mixed: the 62.2% QoQ revenue jump is directionally consistent with Block-7 ramping as guided, but the YoY comparison (the primary read) is still a steep decline, and OPM at ~16.9% sits well below both last year's print and the stated long-term target, so on the margin dimension guidance is being missed so far. This filing carries no attached press release or MD&A commentary, so management's own characterization of the quarter cannot be cross-checked here. The quarter's other corporate developments — a new Company Secretary appointed October 3, 2026, trading-window closure from September 26 ahead of results, and the 31st AGM held September 12, 2026 — are administrative and don't bear on the numbers. H1 FY27 cumulative consolidated revenue of ₹37.65 Cr (down ~31.5% YoY) and PAT of ₹2.75 Cr (down ~67.3% YoY) confirm the weakness spans both quarters of the half, not just this one.

31 Oct 2026, 05:31 pm

Corporate Events

Board MeetingSGRL
2026
31Oct

Board Meeting

The meeting of the Board of Directors of the Company is sche…

BSE Filing ↗
Board MeetingSGRL
2026
3Oct

Board Meeting

The Board of Directors considered and approved the resignati…

BSE Filing ↗
Board MeetingSGRL
2026
12Sep

Board Meeting

The 31st Annual General Meeting ("AGM") of the Company shall…

BSE Filing ↗
Board MeetingSGRL
2026
12Aug

Board Meeting

A meeting of the Board of Directors of the Company is schedu…

BSE Filing ↗
Board MeetingSGRL
2025
19May

Board Meeting

Audited Financial Results (Standalone and Consolidated) of t…

BSE Filing ↗
Board MeetingSGRL
2024
28Sep

Board Meeting

Forfeiture Of Partly Paid-Up Equity Shares Issued On Right'S…

BSE Filing ↗
Board MeetingSGRL
2024
12Feb

Board Meeting

Consider and approve Unaudited Financial Results for the qua…

BSE Filing ↗
Board MeetingSGRL
2024
8Feb

Board Meeting

Revision in payment period for Rights Issue

BSE Filing ↗
Board MeetingSGRL
2024
7Feb

Board Meeting

Outcome of the Rights Issue Committee

BSE Filing ↗
Board MeetingSGRL
2024
25Jan

Board Meeting

Consider and approve first and final call on outstanding sha…

BSE Filing ↗
Board MeetingSGRL
2023
10Nov

Board Meeting

consider and approve the Unaudited Financial Results for the…

BSE Filing ↗